The diagnosis of spinal cord lymphoma is often delayed due to the high risks associated with a spinal cord biopsy, the rarity of the disease, and the lack of specificity of its clinicoradiological ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

Ossification of the posterior longitudinal ligament (OPLL) is a progressive spinal disease characterized by ectopic bone ...

A neurosurgeon and a neuroscientist discover promising new ways to help people with spinal cord injuries walk again ...

More than 15 million people worldwide are living with spinal cord injury (SCI), which can affect their sensory and motor ...

Spinal cord compression (SCC) occurs in 5% to 30% of the oncology population and affects patient function, comfort, and general quality of life. Patients with lung cancer, breast cancer ...

The FDA has approved Evrysdi in tablet form for patients with spinal muscular atrophy aged 2 years and older who weigh more ...

Spinal cord injury (SCI) remains the most serious complication of repairing descending thoracic and thoracoabdominal aortic aneurysms, with endovascular ...

Lineage Cell Therapeutics (LCTX) announced that the Company has initiated the DOSED clinical study. The DOSED study will evaluate the safety ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

An allogeneic stem cell-derived transplant, OPC1 helps restore or increase the functional activity in SCI patients. It is tailored to replace the spinal cord cells that are either ...

Multilevel decompression exhibited comparable postoperative outcomes with that of single-level decompression in patients with lumbar spinal stenosis.